What's the best strategy for biomarker-guided antibiotic therapy in sepsis?
Open Access
- 2 February 2026
- journal article
- Published by Associação de Medicina Intensiva Brasileira in Critical Care Science
- Vol. 38, e20260340
Abstract
No abstract availableThis publication has 10 references indexed in Scilit:
- Reassessing Procalcitonin-Guided Antibiotic Therapy in Critically Ill Patients With Sepsis: Lessons From the ADAPT-Sepsis TrialClinical Infectious Diseases, 2025
- Biomarker-Guided Antibiotic Duration for Hospitalized Patients With Suspected SepsisJAMA, 2025
- Benefits and Harms of Procalcitonin- or C-Reactive Protein-Guided Antimicrobial Discontinuation in Critically Ill Adults With Sepsis: A Systematic Review and Network Meta-Analysis*Critical Care Medicine, 2024
- Procalcitonin-guided antibiotic therapy may shorten length of treatment and may improve survival—a systematic review and meta-analysisCritical Care, 2023
- Use of C-reactive protein to guide the antibiotic therapy in hospitalized patients: a systematic review and meta-analysisBMC Infectious Diseases, 2023
- How to use biomarkers of infection or sepsis at the bedside: guide to cliniciansIntensive Care Medicine, 2023
- Biomarkers in the ICU: less is more? NoIntensive Care Medicine, 2020
- Do we need new trials of procalcitonin-guided antibiotic therapy?Critical Care, 2018
- Procalcitonin-guided interventions against infections to increase early appropriate antibiotics and improve survival in the intensive care unit: A randomized trial*Critical Care Medicine, 2011
- Procalcitonin kinetics within the first days of sepsis: relationship with the appropriateness of antibiotic therapy and the outcomeCritical Care, 2009